The IP was developed by Theragnostics Ltd, which was acquired by Ariceum earlier this year.
The patents have been sub-licensed exclusively to Advance Accelerator Applications (AAA) and apply to the technology underpinning AAA’s Ga-68 HBED-PSMA-11 production kit, branded Locametz.
To date, the production of Ga-68 radiopharmaceuticals has involved a multistep approach, which limits the number of patient doses that can be produced at any one time.
Theragnostics’ Ga-68 technology platform enables the production of multiple doses of Ga-68 HBED-PSMA-11 in a single vial, in one simple step.
Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: “We are pleased that this IP has been granted so soon after our recent acquisition of Theragnostics, highlighting our progress and commitment to developing a pipeline of targeted radiotherapy innovations."
"We are proud to be contributing with this IP to the success of PSMA diagnostics, specifically Locametz, which represents an alternative pathway for PMSA PET imaging of patients.”
Greg Mullen, Chief Operating Officer of Ariceum Therapeutics and co-inventor of the patent, added: "This technology simplifies the production of Ga-68 PSMA for the benefit of thousands of patients around the world, which is incredibly rewarding to see."
"The granting of these patents represents another important milestone towards meeting anticipated increased demand for PSMA PET imaging of patients, following the publication of recent positive data demonstrating the benefit of radioligand therapy in prostate cancer.”
